A Celebration of Technology and Innovation, Program and Reception
Tuesday, April 1, 2008, 4 to 7 p.m.
Emory Conference Center, Silver Bell Pavilion, 1615 Clifton Rd., Atlanta 30322
404-727-1785 or email firstname.lastname@example.org
Max Wallace, CEO, TheraLogics
Start-up of the Year: GeoVax, Inc.
GeoVax is an Atlanta biotechnology company created to develop, test and commercialize novel vaccines for infectious diseases, including HIV. The company's lead candidate vaccine for HIV is currently in human clinical trials. The vaccine technology was licensed from Emory, based on research by Harriet Robinson, PhD, conducted at the Yerkes National Primate Research Center and the Emory Vaccine Center, along with colleagues at the National Institutes of Health and the Centers for Disease Control and Prevention. In 2007 the National Institutes of Health awarded GeoVax a $15 million grant to continue its groundbreaking research on this promising vaccine.
Deal of the Year: Therapeutic Treatment of Chronic Infections
In 2007 Emory University executed a multi-institutional licensing agreement for the development of therapeutics to treat chronic infections such as HCV and AIDS, based on discoveries by Rafi Ahmed, PhD, and his colleagues at the Emory Vaccine Center. Dr. Ahmed is director of the Vaccine Center and a Georgia Research Alliance Eminent Scholar.
Innovation of the Year: Destination Emory Carpool Technology
John Notarantonio, a senior database warehouse developer for Emory's Technology Services, hopes to reduce the number of drivers with a novel "matchmaking" service that makes finding carpooling partners quick and convenient. Emory's employees already have access to the service through Destination Emory, an initiative that encourages alternative commuting options. Through Emory's Technology Transfer Office, Notarantonio was paired with corporate executive Ron Tolliver to form G2EcoSolutions and explore the commercial potential of EcoRide, an enabling technology designed to stimulate growth in carpooling.
Significant Event of 2007: Triptcor Pharmaceuticals
Emory chemist Dennis Liotta and colleagues have developed a series of analogs based on the small molecule triptolide, the active ingredient found in the Triptergium Wilfordii hook F (TWHF) root -- a holistic medicine used by the ancient Chinese. In 2007 Liotta and colleagues founded the pre-incorporated start-up company Triptcor Pharmaceuticals. Triptcor was the winner of the $100,000 grand prize in the first annual BIO/plan competition at the SEBIO Investor Forum.
Emory University's technology transfer program has one of the most robust product pipelines of any university in the country, with one of the nation's leading programs for guiding technology developed in the laboratory through the patenting and licensing process to the marketplace and into the hands of consumers and patients.
The program has resulted in 16 licensed therapeutic products already in the marketplace and 38 licensed therapeutic products in various stages of drug discovery, clinical development or regulatory approval. In addition, 37 companies have been started around Emory's technology, leading to nine publicly traded companies and seven companies selling products on the market.